McKesson Corporation (MCK DU) stock market data APIs
€668.4923
-8.32(-1.2%)
as of October 17, 2025
Try our APIs with
free plan!
McKesson Corporation Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for MCK.DU.
Prev. Close
668.4923
Open
660.1685
High
667.244
Low
653.9246
52 wk Range
454.4004-680.2
Market Cap
31 513 M
Dividends (Yield)
0.0098
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get McKesson Corporation data using free add-ons & libraries
Get McKesson Corporation Fundamental Data
McKesson Corporation Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
McKesson Corporation News
New
How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory
Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco36...
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) closed at $786.00 in the latest trading session, marking a +1.36% move from the prior day. This change outpaced the S&P 500's 0.53% gain on the day. At the same time, the Dow added 0.52...
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharmaceutical Services WST is scheduled to release third-quarter 2025 results on Oct. 23, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 2...
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
DETROIT, October 16, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
